Syndax Pharmaceuticals Q4 2023 GAAP EPS $(1.00) Misses $(0.99) Estimate
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals reported a Q4 2023 GAAP EPS of $(1.00), missing the consensus estimate of $(0.99) by 1.01%.
February 27, 2024 | 9:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syndax Pharmaceuticals reported a Q4 2023 GAAP EPS of $(1.00), missing the consensus estimate by 1.01%.
Missing earnings estimates, even by a small margin, can negatively impact investor sentiment and stock price in the short term. The close miss suggests a slight underperformance compared to market expectations, which could lead to a negative reaction in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100